Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced significant hair regrowth over eight months using 0.5mg dutasteride, 2.5mg oral minoxidil, and 5% topical minoxidil, with plans to continue treatment and update at the one-year mark. They reported no side effects and started derma stamping to enhance results.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

The user experienced significant hair regrowth after 11 months using 0.5 mg dutasteride and 5 mg oral minoxidil daily, initially using a topical treatment with finasteride, minoxidil, and tretinoin. They reported no side effects, except for increased body hair and longer eyelashes, and switched from finasteride to dutasteride for more regrowth.

The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

The user experienced significant hair regrowth over a year using topical finasteride (0.1%) and minoxidil (7%), along with Ketoconazole shampoo, and recently switched to dutasteride and plans to add oral minoxidil. They managed side effects like oily skin and itchiness with a corticosteroid and chose topical treatments initially to limit systemic exposure.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

The conversation discusses a hair loss treatment regimen including oral dutasteride, oral minoxidil, tadalafil, and the recent addition of RU58841. The user shares experiences with these treatments, noting significant hair regrowth and stabilization, and discusses the cost and preparation of RU58841.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

The user experienced hair loss improvement after 3.5 months using a regimen of finasteride, dutasteride, oral minoxidil, dermarolling, and a daily hair/skin/nails vitamin. They noted their hair became thicker, darker, and grew faster with no side effects, unlike their previous unsuccessful attempt with finasteride alone.

The user Consistent-Gene1334 shared their positive results in regrowing hair by using topical minoxidil and oral finasteride. Other users in the conversation praised the results and discussed the effectiveness of these treatments for diffuse thinning.

User gained hair with topical minoxidil and finasteride, then experienced shedding after starting pyrilutamide. After 12 weeks, new hairs grew and existing hairs thickened, hoping for more improvement in a year.

The user shared 11 months of progress using oral finasteride and minoxidil for hair regrowth, reporting no side effects. Feedback from others noted improved hair thickness and health.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.

The conversation is about a user's one-year hair loss treatment using dutasteride, oral and topical minoxidil, ketoconazole, tretinoin, and PRP. Users discuss treatment effectiveness, potential issues with diffuse thinning, and sourcing affordable treatments.

Combining pyrilutamide and alfatradiol might be as effective as finasteride for hair maintenance. The user plans to try this combination alongside minoxidil and keto shampoo, hoping for improved hair thickness.

Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

A 49-year-old male switched from Finasteride to Dutasteride 2.5 mg daily, along with oral Minoxidil 5 mg, resulting in significant hair regrowth and stopping hair loss after six months. Despite initial side effects like adrenaline spikes and urinary issues, the user is satisfied with the results and plans to continue the treatment.

A user found a successful hair loss treatment using a combination of finasteride, dutasteride, minoxidil, and RU58841. They plan to switch to a purely topical regimen with finasteride, RU58841, and minoxidil.

The conversation is about a 29-year-old male using finasteride until November 2024, then switching to dutasteride 0.5mg daily and adding minoxidil in February 2025, with noticeable hair regrowth and no side effects. Users comment positively on the progress, including improved hair in the front and increased armpit hair.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

An 18-year-old is using a high-dose hair loss treatment with 40mg daily dutasteride, finasteride, minoxidil, tretinoin, and topical bicalutamide. Despite health risk concerns, especially liver issues, they report hair regrowth progress and intend to continue the regimen.

The user is using finasteride, minoxidil, and microneedling for hair regrowth and has noticed some improvement after nine weeks. They report no significant side effects and plan to continue the treatment to see further results.